Quality of Life Associated With a Low-Risk Screening Program for Ovarian Cancer
|Study Design:||Observational Model: Case-Only
Time Perspective: Prospective
|Official Title:||Quality of Life Associated With a Low-Risk Screening Program for Ovarian Cancer|
- Mean Scores on Each Quality of Life Instrument (Surveys) [ Time Frame: Baseline quality of life data collected, and if/when return to clinic due to abnormal test results. ] [ Designated as safety issue: No ]Descriptive, written, self-report, quality of life instruments used.
- To find out whether elevated CA 125 levels affect participants in terms of cancer worries or concerns. [ Time Frame: 8 Years ] [ Designated as safety issue: No ]
|Study Start Date:||February 2002|
|Estimated Primary Completion Date:||February 2018 (Final data collection date for primary outcome measure)|
Low Risk OVCA
Patient that is participating in an ovarian cancer (OVCA) screening program.
Questionnaires lasting up to 30 minutes.
Other Name: Survey
Participants in this study will be asked to complete several questionnaires. Participants will be able to fill out the questionnaires in the clinic or if necessary, they can complete them at home. Pre-addressed and stamped envelopes will be provided to mail back if they are completed at home. The questionnaires involve quality of life issues, concerns or worries about cancer risk and beliefs about cancer. It will take 30 minutes or less to complete the questionnaires.
The completed questionnaires can be returned to the research nurse or if the participant prefers or they can be returned to the researchers in the self-addressed stamped envelope that is provided.
This is an investigational study. This study will involve 2400 women who are participating in an ovarian cancer screening program. All will be enrolled at MD Anderson.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00511641
|Contact: Charlotte C. Sun, DrPH||713-745-4380|
|United States, Texas|
|University of Texas MD Anderson Cancer Center||Recruiting|
|Houston, Texas, United States, 77030|
|Principal Investigator: Diane C. Bodurka, MD|
|Principal Investigator:||Diane C. Bodurka, MD||M.D. Anderson Cancer Center|